SLU-PP-332 Oral 100×250mcg — Pan-ERR Exercise Mimetic Tablets

Zoom

99,00 €

Tax included • Free delivery from 99€

+4,95 € in loyalty cashback, with an account. Create my account

Only 4 left, flying off the shelf!

Next dispatch: Tuesday, September 8

Subscription

89,10 €-10 %instead of 99,00 €

-10 % for life on each cyclePause, skip or cancel in 1 clickNo commitment, no hidden fees

SLU-PP-332 Oral 250mcg is the pre-dosed tablet formulation of the pan-ERR agonist small organic molecule that made scientific headlines in 2023 with its publication in Nature Metabolism (Billon et al.) under the mediatized "exercise in a pill" label. Each bottle contains 100 tablets of 250mcg, i.e. 25mg of active SLU-PP-332 per bottle, packaged for RUO preclinical protocols on animal models and cell culture.

SLU-PP-332's pharmacological positioning is that of a synthetic agonist of all three paralogs ERRalpha, beta, gamma (Estrogen-Related Receptors), orphan nuclear receptors discovered by Vincent Giguere in 1988. ERRs orchestrate the oxidative transcriptional program of skeletal muscle, brown adipose tissue and liver: mitochondrial biogenesis, oxidative phosphorylation, fatty acid beta-oxidation, type I muscle fiber specification. Pan-ERR activation by SLU-PP-332 bypasses the need to stimulate PGC-1alpha via physical exercise, making it the first credible "exercise mimetic" class candidate with complete pharmacokinetic profile.

This low dose (250mcg / tablet) is optimal for titration and exploratory dose-response protocols: mapping the ERR activation curve at low exposure, long chronic protocols (> 12 weeks) where logistical stock buildup becomes critical, and pharmacokinetic experiments (AUC, Cmax, half-life) on rodent models where fine dose-response resolution is required.

Lot certified by HPLC certificate of analysis exceeding 98%, mass spectrometry confirming theoretical chemical structure (pyrrole carboxamide, approximately 395 Da molecular weight). Tablet format formulated with inert pharmaceutical excipients compatible with oral rodent administration. Room temperature storage, > 24 months stability in sealed bottle.

Use strictly reserved for RUO preclinical research (rodents, cell culture). SLU-PP-332 has not been approved by any health authority (FDA, EMA, ANSM) for human use. The "exercise in a pill" media coverage in mainstream press does not reflect the current state of scientific knowledge: no human clinical trial has been conducted, human pharmacokinetics remain entirely uncharacterized.

Science

01
Mechanism of action

ERR receptors — Orphan nuclear receptor family

Estrogen-Related Receptors (ERRalpha, beta, gamma) were isolated in 1988 by Vincent Giguere (Nature 331:91) based on strong sequence homology with the estrogen receptor alpha (ESR1) in their DNA-binding (DBD, 68% identity) and ligand-binding (LBD, 36% identity) domains. This structural proximity stops there: ERRs do not bind 17beta-estradiol or any other endogenous estrogen, their ligand pocket is too narrow. They have long been considered strict orphans — no endogenous physiological ligand has been formally identified to date.

The three paralogs show preferential tissue expression:
- ERRalpha (ESRRA): ubiquitous expression with enrichment in high-energy-demand tissues — skeletal muscle (type I oxidative fibers), myocardium, brown adipose tissue (BAT), renal cortex, liver.
- ERRbeta (ESRRB): embryonic stem cells, inner ear, placenta.
- ERRgamma (ESRRG): skeletal muscle, myocardium, brain, adult liver.

Transcriptional mode of action is constitutive: ERRs occupy their DNA response elements (ERRE, 5'-TNAAGGTCA-3') and recruit transcriptional machinery even in the absence of ligand. The intensity of their activity depends on interaction with co-activators, foremost PGC-1alpha (and secondarily PGC-1beta). PGC-1alpha is an inducible transcriptional co-activator whose muscle expression is massively increased by endurance exercise, cold exposure (in BAT), and prolonged fasting (in liver) — three physiological contexts characterized by increased oxidative energy demand.

Exercise - PGC-1alpha - ERR - mitochondria axis

The molecular architecture of the endurance exercise response, elucidated by Bruce Spiegelman (Puigserver 1998 Cell, Lin 2002 Nature, Wu 1999 Cell) and consolidated by a subsequent corpus, breaks down as follows:

1. Exercise signal — Prolonged muscle contraction -> cytosolic Ca2+ rise, AMP/ATP rise -> CaMK + AMPK + p38 MAPK activation -> transcription factor phosphorylation (MEF2, CREB).
2. PGC-1alpha induction — Activated factors increase PPARGC1A (PGC-1alpha) gene transcription in myocyte nuclei.
3. ERR co-activation — PGC-1alpha binds ERRs (primarily ERRalpha in muscle), dramatically amplifying their transcriptional activity on genomic ERREs.
4. Oxidative gene reprogramming — ERRs activate hundreds of target genes: mitochondrial biogenesis (NRF1, TFAM), oxidative phosphorylation (complex I, II, III, IV, V subunits), fatty acid beta-oxidation (CPT1B, MCAD, LCAD), Krebs cycle (IDH3, SDHA), type I fiber specification (myoglobin, Myh7, slow troponins), angiogenesis (VEGF-A).
5. Adaptive phenotype — After several weeks: increased mitochondrial number and density per fiber, shift from type IIa/IIx toward type I oxidative fibers, increased muscle capillarization, improved maximum aerobic capacity (VO2max), increased endurance.

Pharmacological mode of action of SLU-PP-332

SLU-PP-332 is a pan-ERR synthetic agonist that activates all three ERRalpha, beta, gamma paralogs with sub-micromolar potency. It binds into the ERR ligand pocket and stabilizes the receptor's active conformation, increasing its affinity for co-activators (PGC-1alpha and alternative co-activators) even in the absence of exercise-induced PGC-1alpha induction. The molecular result is direct pharmacological activation of the oxidative transcriptional program, bypassing the physical activity prerequisite.

In mice treated for 4 weeks with SLU-PP-332 (Billon 2023, 10-30 mg/kg orally or IP):
- Skeletal muscle: increased mitochondrial content (mitochondrial/nuclear DNA +30-50%), slow-oxidative fiber shift, increased beta-oxidation enzymatic capacity, treadmill endurance increase +45 to +70%.
- Brown adipose tissue (BAT): increased UCP1 expression, increased basal thermogenesis, increased energy expenditure.
- Liver: steatosis reduction in MAFLD (high-fat diet) models, improved glucose tolerance.
- Total fat mass: significant reduction in induced obesity models, without concomitant food intake reduction (the effect is truly energetic uncoupling via expenditure, not caloric restriction).

The preclinical side effect profile is favorable over 4 weeks: no pathological cardiac hypertrophy (some ERRalpha myocardial effects are physiological, dose is calibrated to remain in the adaptive range), no hepatic toxicity, no mitogenic signal at tested doses. Long-term tolerance (>12 weeks) and in humans remains uncharacterized.

Clinical data

02Clinical studies

Pivotal publications — Burris laboratory and successors

The discovery of SLU-PP-332 is part of a medicinal chemistry program led by Thomas Burris (at Scripps Florida, then Saint Louis University, now University of Florida) on orphan nuclear receptor modulators. The screening and structure-activity (SAR) optimization process that led to SLU-PP-332 spans several years, with multiple related chemotypes (SLU-PP-915, SLU-PP-322).

Foundational publications:

- Billon et al. (Nature Metabolism 2023, 5:9) — Pivotal publication. Burris team. Demonstrates in male C57BL/6J mice (4 weeks of treatment, 30 mg/kg IP once daily): 45-70% treadmill endurance increase, increased aerobic capacity measured by indirect calorimetry, 13% reduction of total fat mass in diet-induced obesity model, improved glucose tolerance, muscle transcriptional signature reproducing 80% of genes induced by a 4-week endurance training protocol. This paper crystallized media attention with the "exercise in a pill" designation.
- Xu et al. (Molecular Metabolism 2023) — Demonstration of SLU-PP-332 protective effect in murine metabolic steatohepatitis (MASH / NASH) models. Reduced intracellular hepatic lipids, reduced F2-F3 fibrosis, improved histological NAS score.
- Park, Billon, Burris (SAR publications 2022-2023) — Report structure-activity and pan-ERR profiles.
- Burris reviews 2024-2025 — Consolidation of the ERR rationale as an emerging therapeutic target in metabolic disease.

Scientific context of the ERR field

- Giguere et al. (Nature 1988, 331:91) — Discovery of ERRs by homology with the estrogen alpha receptor.
- Puigserver et al. (Cell 1998, 92:6) — Discovery of PGC-1alpha as the central co-activator of the oxidative / thermogenic program.
- Lin et al. (Nature 2002, 418:6899) — PGC-1alpha as inducer of the type I oxidative fiber switch in skeletal muscle.
- Wu et al. (Cell 1999, 98:1) — Molecular basis of the exercise response via PGC-1alpha.
- Mootha et al. (PNAS 2004) — ERRalpha as an obligate partner of PGC-1alpha for mitochondrial gene activation.
- Villena et al. (J Biol Chem 2007) — Specific role of ERRalpha in skeletal muscle for the oxidative signature.

Earlier ERR modulators (different chemotypes)

Before SLU-PP-332, several pharmacological agents acted on ERRs, but with less advanced profiles:
- XCT-790 (ERRalpha inverse agonist) — Research tool blocking ERR signaling, no exercise-mimetic utility.
- DY131 (selective ERRbeta/gamma agonist) — Specifically activates ERRbeta/gamma, not ERRalpha.
- GSK4716 (ERRbeta/gamma agonist) — Academic pharmacological tool.

SLU-PP-332 represents the first pan-ERR agonist with a pharmacokinetic profile compatible with advanced preclinical development (oral bioavailability, half-life compatible with 1-2x daily dosing, off-target selectivity against the nuclear receptor family).

Corpus limitations

The SLU-PP-332 corpus remains young (pivotal publication September 2023). Major limitations:
- No human clinical trial to date. No human pharmacokinetic data, no validated human dose.
- Data limited to male rodents — most Billon 2023 data concern male C57BL/6J mice. Effects in females, rats, other species poorly characterized.
- Limited treatment duration — most experiments < 4-8 weeks. Chronic tolerance > 6 months not documented.
- Chronic cardiac effects to characterize — ERRalpha plays a physiological cardiac role, but chronic pan-ERR stimulation could theoretically induce pathological cardiac hypertrophy.
- No drug interaction data — human CYP450 metabolism not characterized, potential for interaction with concomitant drugs unknown.

Regulatory context

SLU-PP-332 is a preclinical research molecule only. No health authority (FDA, EMA, ANSM) has evaluated its safety or efficacy in humans. Its commercial availability is limited to the RUO (Research Use Only) circuit for academic and industrial laboratories. Any human use is outside any regulatory framework and without safety guarantees.

No references yet for this peptide — search PubMed for associated scientific literature.

The listed studies are provided for documentation and research purposes only. They do not constitute a therapeutic indication nor a recommendation for human use. This product is strictly for laboratory use only (RUO).

Lab workflow

03
Research protocols

Pre-dosed tablet format: the logistical revolution for long protocols

SLU-PP-332 250mcg tablets (25mg total per bottle of 100 units) are formulated for direct oral (PO) administration in rodents and cell culture, with no organic solvent reconstitution step. This formulation eliminates the DMSO/PEG-400/saline system imposed by the lyophilized powder version and stabilizes dosing at unit precision over multi-week protocols.

Preclinical rodent use (PO protocol)

The pivotal Billon 2023 (Nature Metabolism) publication validates the oral route as an effective administration route for SLU-PP-332, with satisfactory reported bioavailability in C57BL/6J mice. Xu 2023 (Molecular Metabolism) confirms oral efficacy on metabolic phenotypes (hepatic steatosis, mitochondrial biogenesis) at 10-50 mg/kg/day doses.

- Reference exercise-mimetic dose: 30 mg/kg/day PO in 20-25 g mice = 0.6-0.75 mg/day = approximately 2-3 tablets of 250mcg or 1-2 tablets of 500mcg per administration.
- Frequency: 1 daily dose documented (Billon 2023). Some exploratory protocols use 2x/day fractionation.
- Typical duration: 4 weeks (endurance dose) to 8 weeks (metabolic steatosis dose).

Practical administration

Tablets can be administered by intragastric gavage (syringe with flexible oro-gastric probe) after crushing and suspension in inert vehicle (0.5% methylcellulose, 0.1% tween 80), or integrated into chow (placebo-formulated adapted). Gavage guarantees a precise individual dose; dietary integration simplifies long-duration protocols.

Hypothetical human extrapolation

BSA FDA extrapolation (factor 0.081) from the 30 mg/kg mouse dose gives a theoretical HED of ~2.4 mg/kg, i.e. ~170 mg/day for a 70 kg human. This estimate is purely theoretical: no human clinical trial has validated this dose, and human pharmacokinetics (oral absorption, half-life, CYP450 metabolism, excretion) remain entirely uncharacterized. SLU-PP-332 has not been approved by any health authority (FDA, EMA, ANSM) for human use.

Advantage of tablet format vs lyophilized powder

- Room temperature stability: no strict cold chain, simplified transport and storage.
- Standardized dose: elimination of weighing error (the 10mg powder requires an analytical balance 0.01 mg).
- Chronic protocol compatibility: for an 8-12 week study with 10 animals, DMSO solution buildup becomes constraining (20-30 mL stock, crystallization risk, daily extemporaneous prep). The pre-dosed tablet eliminates this constraint.
- Traceability: each tablet = one discrete dose unit, facilitating blinding and protocol audit.

Critical RUO warning

SLU-PP-332 oral tablets are strictly intended for preclinical research on laboratory animal models and cell culture. The "exercise in a pill" media coverage generates speculative demand exceeding available human scientific data. Extrapolating rodent doses to humans is hazardous; no human clinical trial has been conducted.

Asepsis

Disinfect surfaces and stoppers (70% alcohol).

Solvent

Draw the required volume of bacteriostatic water.

Introduction

Inject gently against the vial wall (avoid direct jet on powder).

Solubilization

Roll the vial gently. Do not shake vigorously (degradation risk).

Solution storageOnce reconstituted: 2-8°C (refrigerator).

WarningTheoretical tool for chemical handling. Does not constitute medical advice.

I open the dilution calculator

What is normal on arrivalThe observations that worry customers, and are not defects

The vial carries no individual label. That is our standard packaging, not a downgraded vial.
The parcel is plain. Nothing on the outside indicates the contents or the brand name.

What is not normal: a cracked vial, an uncrimped cap or a stopper that moves, powder that has liquefied or changed colour. In those specific cases, write to us with a photo and we take the vial back.

Handling

04Storage & handling

Storage of SLU-PP-332 tablets (oral format)

Unlike the lyophilized powder which requires a -20 C freezer, SLU-PP-332 oral tablets benefit from enhanced pharmaceutical stability through their excipient matrix:

- Temperature: ambient (15-25 C) accepted for routine storage, or +4 C refrigerator for extended storage (> 12 months). Avoid thermal fluctuations and direct sun exposure.
- Atmosphere: original sealed bottle (integrated silica gel desiccant), relative humidity < 60%. Reclose immediately after each sampling to limit humidity absorption by tablets.
- Light: opaque amber bottle. Avoid any direct UV exposure.
- Stability: > 24 months in original sealed bottle at controlled ambient temperature. Verify manufacturing date on the COA.

Good laboratory practices

- Sampling: use clean forceps or dosing spoon. Never handle tablets with bare hands (skin contamination, possible absorption through moist skin).
- Gloves: nitrile recommended during handling for gavage.
- Extemporaneous suspension: if crushing and suspension in vehicle (methylcellulose, tween), prepare on the same day. Post-suspension stability limited to 24h at +4 C.

Shipping and receipt

Delivery at ambient temperature acceptable (documented stability). Insulated pack + ice pack in summer (> 25 C ambient) recommended but not required. On receipt: place the sealed bottle in dry location, shielded from light.

Disposal

Unused or expired tablets must be disposed through the laboratory chemical waste stream (DASRI), never in household trash. Unused extemporaneous suspensions follow the biological waste stream per the establishment's protocol.

01Why choose the oral 250mcg format over the lyophilized 10mg powder?

The choice depends on the protocol. The **10mg lyophilized powder** remains the reference for: (1) intraperitoneal or subcutaneous injection (IP/SC routes used in Billon 2023 to standardize systemic exposure), (2) fine pharmacokinetics with microgram-precise dosing, (3) cell culture experiments requiring a DMSO stock solution at precise concentration. The **oral 250mcg format** is optimal for: (1) **multi-week chronic PO protocols** (Billon 2023 validates oral route), (2) **no reconstitution** (no daily DMSO/PEG-400/saline prep), (3) **room temperature stability** (no -20 C cold chain), (4) **dose standardization** (elimination of weighing error). For a dose-response titration protocol, the oral tablet is logistically superior.

02How many 250mcg tablets to reproduce the Billon 2023 dose (30 mg/kg mouse)?

For a standard 20-25 g C57BL/6J mouse: daily dose = 20 × 0.030 = **0.60 mg** to 25 × 0.030 = **0.75 mg** of SLU-PP-332. With 250mcg tablets: **2.4 to 3.0 tablets / day / mouse** (2-3 tablets per daily administration). For a 4-week protocol on 10 mice, this represents approximately 840 tablets, i.e. 9 bottles of 100 tablets. The 5-bottle pack with 10% discount is often the economical choice.

03Does the tablet formulation modify bioavailability vs powder?

The **oral bioavailability of SLU-PP-332 is reported as satisfactory** in Billon 2023 and Xu 2023 (PO experiments use the powder directly in DMSO/PEG suspension). The tablet formulation uses inert pharmaceutical excipients (microcrystalline cellulose, magnesium stearate, colloidal silica) that do not substantially modify the intestinal dissolution of a hydrophobic small molecule like SLU-PP-332. **Limitation**: no head-to-head PO powder vs PO tablet comparative study has been published. Bioavailability data remain those of the powder-in-suspension formulation. For precision PK experiments, powder in DMSO suspension remains the reference; the tablet is optimal for logistical convenience on chronic protocols.

04Is SLU-PP-332 really an "exercise pill" as the press claims?

Only partially, and strictly in mice. The Billon 2023 Nat Metab publication demonstrates that SLU-PP-332 reproduces approximately **80% of the muscle transcriptional signature induced by 4 weeks of endurance training in mice**, with a treadmill endurance increase of +45 to +70%. That is mechanistically remarkable. **However**: (1) real exercise generates multi-system benefits (cardiovascular, cognitive, bone, psychological) that SLU-PP-332 does not reproduce; (2) no human clinical trial has been conducted, the effect in humans remains entirely hypothetical; (3) media coverage far exceeds available scientific data.

05What dose is used in mice in the scientific publications?

The reference dose in Billon 2023 Nat Metab and Xu 2023 Mol Metab is **30 mg/kg/day intraperitoneally (IP)** in male C57BL/6J mice, over 4 weeks. Some exploratory studies report 10 to 50 mg/kg by oral (PO) or intraperitoneal route. **Human extrapolation by BSA (FDA factor 0.081)** would give a theoretical HED (Human Equivalent Dose) of approximately 2.4 mg/kg, i.e. about 170 mg/day for 70 kg. This extrapolation is **purely theoretical and unvalidated** — human pharmacokinetics is not characterized.

06Why does SLU-PP-332 specifically target ERR receptors and not other nuclear receptors?

ERRs (Estrogen-Related Receptors alpha, beta, gamma) are the **master nuclear receptors of the oxidative program**: they orchestrate, downstream of PGC-1alpha (the "exercise gene"), the expression of hundreds of genes involved in mitochondrial biogenesis, oxidative phosphorylation, fatty acid beta-oxidation and type I muscle fiber specification. Directly targeting ERRs bypasses the need to induce PGC-1alpha, which normally only rises with exercise, cold or fasting. The Burris team developed SLU-PP-332 to occupy the ERR ligand pocket with selectivity outside the nuclear receptor family (no activity on androgen, estrogen, glucocorticoid or thyroid receptors).

07Are there cardiac risks with SLU-PP-332?

**Theoretical risk not formally characterized.** ERRalpha plays a physiological cardiac role in cardiomyocyte oxidative metabolism. Preclinical 4-week studies (Billon 2023) did not reveal pathological cardiac hypertrophy at the doses used. **However**, chronic prolonged pan-ERR stimulation (> 3-6 months) has not been studied: it could theoretically induce adaptive hypertrophy which, if exceeding the physiological threshold, could become pathological. The total absence of human data makes this characterization speculative. This is one of the points that a hypothetical human phase I trial would need to evaluate.

08What is the oral bioavailability of SLU-PP-332?

Oral bioavailability is **reported as satisfactory but not precisely quantified** in Billon 2023 and Xu 2023 publications (most experiments use the intraperitoneal route to standardize systemic exposure). Oral protocols at 10-50 mg/kg are documented with observed phenotypic effects. In humans, **no oral bioavailability data exist**. Human CYP450 metabolism has not been characterized, drug interaction potential is unknown. These human PK characterizations are precisely what a phase I trial would need to establish.

09Can SLU-PP-332 be combined with physical exercise to amplify effects?

Attractive hypothesis but **not studied to date** in peer-reviewed publications. Theoretically, exercise raises endogenous PGC-1alpha and SLU-PP-332 pharmacologically amplifies the ERR signal: the combination could be additive or even synergistic on mitochondrial biogenesis and the oxidative signature. **In practice**, no study validates this combination, and it remains uncertain whether adding SLU-PP-332 to regular training provides marginal benefit or simply shifts the dose-response curve. This is an interesting avenue for future research protocols on sarcopenia or deconditioning.

Benchmark

Similar peptides

SLU-PP-332 versus other exercise mimetics

The "exercise mimetics" field — molecules pharmacologically reproducing some effects of physical exercise — comprises several distinct mechanistic classes:

- AICAR (5-aminoimidazole-4-carboxamide ribonucleoside) — AMPK activator, pivotal Narkar 2008 Cell publication. Historically the "first exercise mimetic" to receive media attention. Activates AMPK but with a much broader target spectrum, modest endurance effect (+20-40% in mice).
- GW501516 (cardarine) — Selective PPARdelta agonist. Induces muscle beta-oxidation, robustly increases endurance in rodents. Clinically abandoned due to a rat carcinogenic signal (long-term hepatocarcinomas).
- SR9009 (stenabolic) — REV-ERB agonist. Multiple metabolic effects (circadian clock, mitochondria, hepatic lipogenesis). Controversial oral bioavailability, no human data.
- MOTS-c — Mitochondrial peptide (16 aa), Lee 2015 Cell Metab publication. AMPK activation, effect on insulin sensitivity and exercise.
- SLU-PP-332 — Pan-ERR agonist. Most downstream mechanism (directly on nuclear master receptors of oxidative expression), most robust published endurance effect (+70%), most recent and best-controlled Billon 2023 data.

Relative positioning: SLU-PP-332 is the most mechanistically promising molecule in 2024-2025 (directly targets ERRs, masters of the oxidative program, without the limitations of alternative targets like AMPK which also activates undesirable catabolic pathways). The limitation remains the total absence of human data.

SLU-PP-332 versus GLP-1 agonists (semaglutide, tirzepatide)

GLP-1 analogues are the dominant pharmacological class in obesity in 2024-2025 with clinically documented weight reductions of 15 to 25%. GLP-1 mechanism: central action (satiety) + gastric emptying delay + insulin effect. SLU-PP-332 mechanism: peripheral action (muscle, BAT, liver) on oxidative energy expenditure. The two approaches are mechanistically orthogonal: GLP-1 acts on caloric input (reduction), SLU-PP-332 acts on energy output (increase). In theory a combination could be complementary, but no study has explored this avenue.

Clinically, GLP-1 largely outperforms SLU-PP-332 in documented effect magnitude in humans (phase III data vs total absence of human data for SLU-PP-332). SLU-PP-332 remains a research molecule.

SLU-PP-332 versus Tesamorelin + Ipamorelin (GH axis)

Tesamorelin + Ipamorelin stimulates the endogenous GH axis, inducing clinically documented visceral lipolysis and indirect muscle anabolism via IGF-1. SLU-PP-332 acts directly on target tissue (muscle, BAT) via ERRs, without going through the hypothalamic-pituitary axis. Theoretical complementarity: GH stimulates lipolysis and anabolism, ERR stimulates oxidation and mitochondrial biogenesis. No combined study.

SLU-PP-332 versus actual endurance training

Real physical endurance exercise generates a multi-system beneficial pleiotropy that SLU-PP-332 only partially reproduces:
- Muscle oxidative effects: well reproduced by SLU-PP-332 (80% of the transcriptional signature per Billon 2023).
- Cardiovascular effects (blood pressure reduction, endothelial function improvement): partially reproduced, limited data.
- Cognitive effects (BDNF, hippocampal neurogenesis): not documented with SLU-PP-332.
- Bone effects (density, osteoblast force): not documented.
- All-cause mortality benefits: obviously not extrapolable.

SLU-PP-332 is not a substitute for physical exercise, even in mice: it is a potential pharmacological complement for populations unable to engage in physical activity (advanced age, disability, limiting pathology). In this perspective, its potential clinical development would target sarcopenia, cachexia, inflammatory myopathy, or severe deconditioning.

SLU-PP-332 Oral 100 × 250mcg Performance

Physiology

01
Mechanism of action

02Clinical studies

03
Research protocols

Asepsis

Solvent

Introduction

Solubilization

04Storage & handling

Similar peptides

Physiology

Asepsis

Solvent

Introduction

Solubilization

Complementary reagents